ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Bioinformatics"

  • Abstract Number: 1428 • ACR Convergence 2022

    Molecular and Clinical Profiling of Rheumatoid Arthritis Patients Predicts the Response to Rituximab

    Daniel Toro-Domínguez1, José Linares-Blanco1, Raúl López-Domínguez2, Pilar S. López-Garrido2, Georgina Galicia-Rosas1, Pedro Carmona-Sáez2 and Marta Alarcon-Riquelme1, 1Center for Genomics and Oncological Research (GENYO), Granada, Spain, 2University of Granada, Granada, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is one of the most prevalent rheumatic diseases, mainly characterized by chronically painful, swollen joints that can severely impair physical function…
  • Abstract Number: 0536 • ACR Convergence 2022

    Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria

    Andrea Fava1, Laurence S Magder2, Daniel W. Goldman3, Jill Buyon4, Betty Diamond5, Joel Guthridge6, William Apruzzese7, Derek Fine1, Jose Monroy-Trujillo1, Mohamed G. Atta1, Peter Izmirly4, H Michael Belmont8, Anne Davidson5, Maria Dall'Era9, Deepak Rao7, Arnon Arazi10, Nir Hacohen11, Soumya Raychaudhuri7, the Accelerating Medicines Partnership (AMP) RA/SLE12 and Michelle Petri3, 1Johns Hopkins University, Baltimore, MD, 2University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 4NYU Grossman School of Medicine, New York, NY, 5Feinstein Institutes for Medical Research, Manhasset, NY, 6Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Brigham and Women's Hospital, Boston, MA, 8NYU School of Medicine, New York, NY, 9University of California, San Francisco, San Francisco, 10Feinstein Institutes for Medical Research, Melrose, MA, 11Broad Institute, Cambridge, MA, 12Multiple Insitutions

    Background/Purpose: A decline of urine protein-to-creatinine ratio (UPCR) to < 0.5 is associated with better long-term preservation of kidney function in lupus nephritis (LN). UPCR…
  • Abstract Number: 1118 • ACR Convergence 2022

    Monocyte Transcriptomic Analysis Uncovers Heterogeneous Gene Expression Profiles in Systemic Lupus Erythematous (SLE) with and Without Subclinical Atherosclerosis

    Laurel Woodridge1, Elvira Chocano Navarro2, George Robinson1, Paul Ashford1, Kirsty Waddington3, Anisur Rahman4, Christine Orengo5, Ines Pineda-Torra6 and Elizabeth Jury1, 1University College London, London, United Kingdom, 2VIHR, Barcelona, Spain, 3University College London (alumni), London, United Kingdom, 4Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 5ISMB / UCL, London, United Kingdom, 6Cabimer, Sevilla, Spain

    Background/Purpose: A leading cause of mortality in SLE is cardiovascular disease (CVD) through accelerated atherosclerosis: the build-up of cells and lipids in the vascular wall.…
  • Abstract Number: 1473 • ACR Convergence 2022

    Unsupervised Clustering of Lupus Patient-Reported Outcome Data Identifies Patient Groups with Differences in SLEDAI and Physician Global Assessment

    Jack Zent1, Kristy Bell2, Brooke Williams2, Prathyusha Bachali3 and Peter Lipsky4, 1AMPEL BioSolutions LLC, Leesburg, VA, 2AMPEL BioSolutions LLC, Charlottesville, VA, 3AMPEL BioSolutions, Redmond, WA, 4AMPEL BioSolutions, Charlottesville, VA

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous clinical presentations. Patient-reported outcomes (PROs) can aid in the measurement of the burden of…
  • Abstract Number: 0554 • ACR Convergence 2022

    Loss of Synovial Tissue Macrophage Homeostasis Precedes Rheumatoid Arthritis Clinical Onset

    Megan Hanlon1, Mary Canavan2, conor Smith3, Achilleas Floudas4, Nuno Neto5, Qingxuan Song6, Phil Gallagher7, Ronan Mullan8, Conor Hurson9, Barry Moran5, Michael Monaghan5, Sunil Nagpal10, Douglas Veale11 and Ursula Fearon5, 1Molecular Rheumatology, Dublin, Ireland, 2Trinity College, Dublin, Ireland, 3bTrinity College Dublin, Dublin, Ireland, 4Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, 5Trinity College Dublin, Dublin, Ireland, 6Janssen Research and Development, LLC, Spring House, PA, 7St Vincent's University Hospital, Dublin, Ireland, 8Tallaght University Hospital, Dublin, Ireland, 9St Vincents University Hospital, Dublin, Ireland, 10Janssen Research, Collegeville, PA, 11St. Vincent's University Hospital, Blackrock, Dublin, Ireland

    Background/Purpose: Synovial-tissue macrophages significantly contribute to Rheumatoid Arthritis, yet the precise nature/function of macrophage subsets within the inflamed joint remains unexplored. Here we explore the…
  • Abstract Number: 1119 • ACR Convergence 2022

    Investigating Macrophage Heterogeneity in the Esophagus and Lungs of SSc Patients

    Hadijat Makinde1, Carla Cuda1, Miranda Gurra1, Mary Carns2, Kathleen Aren2, Gaurav Gadhvi1, Salina Dominguez1, Jane Dematte3, Darren Brenner4, John Pandolfino5, G. R. Scott Budinger4, Deborah Winter6 and Harris Perlman1, 1Northwestern University, Chicago, IL, 2Northwestern University Division of Rheumatology, Chicago, IL, 3Northwestern University, Elmhurst, IL, 4Northwestern University Feinberg School of Medicine, Chicago, IL, 5Northwestern University, Feinberg School of Medicine, Wilmette, IL, 6Northwestern University, Skokie, IL

    Background/Purpose: Our group has made important contributions to an emerging understanding of monocytes and macrophages as central to SSc pathogenesis. There are numerous studies that…
  • Abstract Number: 1607 • ACR Convergence 2022

    Machine Learning Identifies Biomarker of Non-Response to Methotrexate in Rheumatoid Arthritis

    Vincent Bouget1, Julien Duquesne1, Paul-Henry Cournède2, Bruno Fautrel3, Francis Guillemin4, Pascal de Jong5, Judith Heutz6, Marloes Verstappen7, Annette van der Helm-van Mil8, Xavier Mariette9 and Samuel Bitoun10, 1Scienta Lab, Paris, France, 2Paris-Saclay University - CentraleSupelec, Paris, France, 3Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, 4Université de Lorraine, APEMAC, Vandoeuvre-les-nancy, France, 5ErasmusMC, Hendrik Ido Ambacht, Netherlands, 6Erasmus Medical Center, Rotterdam, Netherlands, 7Leiden University Medical Center, Leiden, Netherlands, 8Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, 9Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 10Paris-Saclay University, Paris, France

    Background/Purpose: Methotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA). Unfortunately, 30% to 40% of RA patients do not respond to MTX with…
  • Abstract Number: 0564 • ACR Convergence 2022

    Identifying Shared Genetic Architecture Between RA and Other Conditions: A Phenome-Wide Association Study

    Harrison Zhang1, Gregory McDermott2, Thany Seyok2, Sicong Huang2, Kumar Dahal2, Sehi L'Yi1, Clara Lea-Bonzel1, Jacklyn Stratton2, Dana Weisenfeld2, Tianrun Cai2, Paul Monach3, Jing Cui2, Chuan Hong4, Tianxi Cai5 and Katherine Liao2, 1Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3VA Boston Healthcare System, Boston, MA, 4Duke University, Durham, NC, 5Harvard TH Chan School of Public Health, Boston, MA

    Background/Purpose: RA shares individual risk alleles with other autoimmune conditions such as type 1 diabetes and celiac disease. However, there are limited studies examining the…
  • Abstract Number: 1120 • ACR Convergence 2022

    Transcriptome-Wide Association Study of Sjögren’s Disease Risk Alleles Identifies Novel Genes with Altered Expression in Minor Salivary Gland and Other Tissues

    Marcin Radziszewski1, Mandi Wiley1, Bhuwan Khatri1, Kandice Tessneer1, Astrid Rasmussen1, Professor Simon Bowman2, Lida Radfar3, Roald Omdal4, Marie Wahren-Herlenius5, Blake Warner6, Torsten Witte7, Roland Jonsson8, Maureen Rischmueller9, Patrick Gaffney1, Judith James1, Lars Ronnblom10, R. Hal Scofield3, Xavier Mariette11, Marta Alarcon-Riquelme12, Fai Ng13, Gunnel Nordmark10, Umesh Deshmukh1, A. Darise Farris1 and Christopher Lessard1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University Hospitals Birmingham, Birmingham, United Kingdom, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Stavanger University, Stavanger, Norway, 5Karolinska Institutet, Stockholm, Sweden, 6National Institutes of Health, Bethesda, MD, 7MH-Hannover, Hannover, Germany, 8University of Bergen, Bergen, Norway, 9RheumatologySA, Adelaide, Australia, 10Uppsala University, Uppsala, Sweden, 11Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 12Center for Genomics and Oncological Research (GENYO), Granada, Spain, 13Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Sjögren's disease (SjD) is an autoimmune disease characterized by reduced function of exocrine glands, but also has systemic manifestations affecting multiple organs, including abnormal…
  • Abstract Number: 1625 • ACR Convergence 2022

    Single Cell and Spatial Transcriptomics Identifies Pathogenic Drivers of Sjogren’s Disease in Humans

    Blake Warner1, Thomas Pranzatelli2, Paola Perez2, Daniel Martin2, Shyh-Ing Jang2, Kalie Dominick2, Eiko Yamada2, Kevin Byrd3, Quinn Easter4, A. Darise Farris5, Christopher Lessard5, Amanda Oliver6, Raquel Bartolome-Casado6, Zohreh Khavandgar1, Sarthak Gupta7, Sarah Teichmann6, Alan Baer8 and John Chiorini2, 1National Institutes of Health, Bethesda, MD, 2NIDCR, Bethesda, MD, 3American Dental Association, Scientific Research Institute, Gaithersburg, MD, 4American Dental Association, Gaithersburg, MD, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Wellcome Sanger Institute, Cambridgeshire, United Kingdom, 7National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 8Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Sjogren's Disease(SjD) is a systemic autoimmune disease characterized by exocrine dysfunction. The pathogenesis is incompletely understood, but involves gene-environment interactions leading to infiltration of…
  • Abstract Number: 0565 • ACR Convergence 2022

    Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissues Using Single-cell Computational Omics

    Juan Vargas1, Nirmal Banda2, Ian Mantel3, Anna Jonsson4, Kevin Wei5, Deepak Rao4, Susan Goodman6, Kevin D Deane7, Jennifer Seifert8, Jennifer Anolik9, Michael Brenner10, Soumya Raychaudhuri4, Accelerating Medicines Partnership RA/SLE4, Michael Holers2, Laura Donlin6 and Fan Zhang8, 1School Public Health Biostatistics Department, Aurora, CO, 2Department of Medicine Division of Rheumatology, Aurora, CO, 3Weill Cornell Medicine, New York, NY, 4Brigham and Women's Hospital, Boston, MA, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 6Hospital for Special Surgery, New York, NY, 7University of Colorado Denver Anschutz Medical Campus, Denver, CO, 8University of Colorado, Aurora, CO, 9University of Rochester Medical Center, Rochester, NY, 10Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune arthritis pathogenesis. In patients…
  • Abstract Number: 1125 • ACR Convergence 2022

    Genomics of JAK-STAT Signaling in Venous Thromboembolism

    Stine R Haysen, Ane Langkilde-Lauesen Nielsen, Per Qvist and Tue Kragstrup, Aarhus University, Aarhus, Denmark

    Background/Purpose: Janus kinase inhibitors (JAKi) have been associated with an increased risk of venous thromboembolism (VTE). This concern limits the use of JAKi-based therapy. Hence,…
  • Abstract Number: 1680 • ACR Convergence 2022

    Module Signatures of Synovial Single-cell States Identify Disease Phenotypes in Early Treatment-naive Rheumatoid Arthritis

    Felice Rivellese1, Elena Pontarini2, Cankut Cubuk1, Alessandra Nerviani1, Liliane Fossati-Jimack1, Anna Surace1, Elisabetta Sciacca3, Katriona Goldmann1, Michele Bombardieri4, Myles Lewis1 and Costantino Pitzalis1, 1Queen Mary University of London, London, United Kingdom, 2William Harvey Research Institute, London, United Kingdom, 3Queen Mary University of London, Biancavilla, Italy, 4Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom

    Background/Purpose: Despite extensive studies, the relationship between circulating and local immune cells and clinico-pathological features of Immune-Mediated Inflammatory Diseases remains unclear. Recently, synovium-specific cell states…
  • Abstract Number: 0633 • ACR Convergence 2022

    Identification of Systemic Lupus Erythematosus Endotypes by Analysis of Inflammatory and Immunologic Gene Expression Signatures

    Erika Hubbard1, Prathyusha Bachali2, Kathryn Kingsmore Allison1, Yisha He1, Michelle Catalina3, Amrie Grammer4 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2AMPEL BioSolutions, Redmond, WA, 3AMPEL BioSolutions, Harvard, MA, 4AMPEL LLC, Charlottesville, VA

    Background/Purpose: One of the hallmarks of SLE is clinical and molecular heterogeneity. Recent work has leveraged next-generation sequencing techniques to identify molecular signatures characteristic of…
  • Abstract Number: 1136 • ACR Convergence 2022

    Stratification of Systemic Lupus Erythematosus (SLE) Patients Based on the Molecular Patterns of Mouse Models

    Maria Rivas Torrubia, Maria Morell, Marta Alarcon-Riquelme and Guillermo Barturen, Center for Genomics and Oncological Research (GENYO), Granada, Spain

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune, chronic and multisystemic autoimmune disorder, which typically affects women and presents high severity and mortality. It is…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 21
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology